替吉奥联合经肝动脉化疗栓塞治疗中晚期肝细胞癌的疗效观察

张呈; 陈昌南; 林云笑; 苏铭俊; 潘岐作; 陈婵娟; 容庭杰; 谢峰

doi:10.3969/j.issn.1001-5256.2014.01.012

替吉奥联合经肝动脉化疗栓塞治疗中晚期肝细胞癌的疗效观察

DOI: 10.3969/j.issn.1001-5256.2014.01.012

广东省江门市新会区人民医院肿瘤血液科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2810
- HTML全文浏览量: 10
- PDF下载量: 589
- 被引次数: 0
出版历程
- 收稿日期: 2013-02-09
- 出版日期: 2014-01-20

Clinical effect of transcatheter arterial chemoembolization combined with tegafur, gimeracil, and oteracil potassium in treatment of advanced hepatocellular carcinoma

Department of Hematology and Oncology, Xinhui People' s Hospital

摘要

摘要:
目的对比观察经肝动脉栓塞化疗（TACE）单用或联合替吉奥治疗中晚期肝细胞癌（HCC）的疗效。方法将2009年8月-2010年10月本院收治的无法手术切除的中晚期HCC患者60例随机分为2组,每组30例。治疗组采用TACE联合替吉奥口服,对照组仅行TACE。观察2组的有效率、疾病控制率、生存率以及不良反应情况。计数资料采用χ2检验;生存分析运用Logrank检验。结果有效率:治疗组63.3%,对照组33.3%,差异有统计学意义（χ2=5.406,P=0.020）;疾病控制率:治疗组86.7%,对照组43.3%,差异有统计学意义（χ2=12.308,P=0.000）。1年生存率:治疗组77.3%,对照组51.5%,差异有统计学意义（χ2=4.593,P=0.032）;2年生存率:治疗组34.8%,对照组10.4%,差异有统计学意义（χ2=4.812,P=0.028）。治疗组、对照组不良反应轻微,主要是恶心呕吐、腹泻和骨髓抑制,为1、2级,对症治疗可缓解,两组比较差异无统计学意义（P>0.05）。结论替吉奥联合TACE术对中晚期HCC有一定的治疗价值,值得进一步探讨。
- 癌,肝细胞 /
- 化学栓塞,治疗性 /
- 替吉奥
Abstract:
Objective To evaluate the clinical effect of transcatheter arterial chemoembolization ( TACE) alone or combined with tegafur, gimeracil, and oteracil potassium ( S- 1) in the treatment of advanced hepatocellular carcinoma ( HCC) . Methods Sixty patients with unresectable advanced HCC, who were admitted to our hospital from August 2009 to October 2010, were randomly divided into treatment group ( n =30) and control group ( n =30) . The treatment group was treated with TACE combined with oral S-1, and the control group with TACE alone. The response rates, disease control rates, survival rates, and adverse reactions of both groups were evaluated. Categorical data were analyzed by chi- square test; survival analysis was performed by Log- rank test. Results Compared with the control group, the treatment group had a significantly higher response rate ( 63. 3% vs 33. 3%, χ2= 5. 406, P = 0. 020) , a significantly higher disease control rate ( 86. 7% vs 43. 3%, χ2= 12. 308, P = 0. 000) , a significantly higher 1- year survival rate ( 77. 3% vs 51. 5%, χ2= 4. 593, P = 0. 032) , and a significantly higher 2- year survival rate ( 34. 8% vs 10. 4%, χ2= 4. 812, P = 0. 028) . Mild adverse reactions ( grade Ⅰ or Ⅱ) were seen in the two groups, including nausea, vomiting, diarrhea, and bone marrow suppression. These adverse reactions could be reduced by symptomatic treatment and showed no significant differences between the two groups ( P > 0. 05) . Conclusion The combination therapy with S- 1 plus TACE is effective in the treatment of advanced HCC and is worth further study.
- carcinoma, hepatocellular /
- chemoembolization, therapeutic /
- gimeracil and oteracil porassium

HTML全文

参考文献(14)

[1]KIM SJ, HAN SW, OH DY, et al.Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma[J].Anticancer Res, 2010, 30 (12) :5245-5250.

[2]MORISE Z, SUGIOKA A, FUJITA J, et al.S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas[J].Hepatogastroenterology, 2007, 54 (80) :2315-2318.

[3]NAKAMURA M, NAGANO H, MARUBASHI S, et al.S-1 treatment against advanced HCC[J].Gan To Kagaku Ryoho, 2006, 33 (Suppl 1) :230-235.

[4]KATAMURA Y, AIKATA H, HASHIMOTO Y, et al.Pilot study of systemic combination therapy with S-1, an oral fluoropyrimidine, and cisplatin for hepatocellular carcinoma with extrahepatic metastases[J].Hepatogastroenterology, 2010, 57 (102-103) :1272-1278.

[5]YAMADA D, WADA H, KOBAYASHI S, et al.A long-term survival case of hepatocellular carcinoma with bone metastasis and inferior vena cava tumor thrombus successfully treated with multidisciplinary therapy[J].Gan To Kagaku Ryoho, 2010, 37 (12) :2670-2267.

[6]YANG BH, XIA JL.Clinical diagnosis and staging criteria for primary liver cancer[J].Chin J Hepatol, 2001, 9 (6) :324. (in Chinese) 杨秉辉, 夏景林.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志, 2001, 9 (6) :324.

[7] MAO JW.Current situation and progress in minimally inva-sive therapy for primary liver cancer[J].Chin Modern Med, 2005, 3 (7) :29-31. (in Chinese) 毛金武.原发性肝癌微创治疗的现状及进展[J].中华当代医学, 2005, 3 (7) :29-31.

[8]LYU HF, ZHANG YX, HAN LL, et al.Clinical observation of Oxaliplatin combined with Gimeracil or Capecitabine in the treatment of advanced gastric cancer in elderly patients[J].China Med Herald, 2012, 9 (23) :61-63. (in Chinese) 吕慧芳, 张延新, 韩黎丽, 等.奥沙利铂联合替吉奥或卡培他滨治疗老年晚期胃癌的临床观察[J].中国医药导报, 2012, 9 (23) :61-63.

[9]BLUM M, SUZUKI A, AJANI JA.A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma[J].Future Oncol, 2011, 7 (6) :715-726.

[10]SAIF MW, SYRIGOS KN, KATIRTZOGLOU NA.S-1:a promising new oral fluoropyrimidine derivative[J].Expert Opin Investig Drugs, 2009, 18 (3) :335-348.

[11]LIU JH, QI SM, CHEN GJ, et al.Compourd tegafur capsules for clinical research progress[J].China Modern Doctor, 2008, 46 (30) :62-63.刘江华, 戚苏明, 陈国俊, 等.替吉奥胶囊临床研究进展[J].中国现代医生, 2008, 46 (30) :62-63.

[12]VARGA M, VALSAMIS A, MATIA I, et al.Transarterial chemoembolization in hepatocellular carcinoma[J].Rozhl Chir, 2009, 88 (8) :434-438.

[13]LAN CH, WANG CY.Progress of TACE for primary liver cancer[J].Current Physician, 2009, 3 (4) :500-502.兰春虎, 王常友.原发性肝癌TACE治疗进展[J].当代医学, 2009, 3 (4) :500-502.

[14]CHEN CN, PAN QZ, HUANG HX, et al.Clinical effect of whole-body hyperthermia combined with transcatheter arterial chemoembolization in treatment of advanced liver cancer[J].J Clin Hepatol, 2006, 33 (3) :220. (in Chinese) 陈昌南, 潘岐作, 黄活勋, 等.体外热疗与TACE结合治疗中晚期肝癌的临床研究[J].临床肝胆病杂志, 2006, 33 (3) :220.

施引文献

资源附件(0)

访问统计